OOIR: Observatory of International Research

Papers

(The H4-Index of Multiple Sclerosis Journal is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Cerebrospinal fluid–related tissue damage in multiple sclerosis patients with iron rim lesions	123
Sars-CoV2 infection in pregnant women with multiple sclerosis	92
Reply to letter to the editor: Olfactory threshold as a biomarker of disease activity	89
Time to move past typical syndromes in the diagnosis of multiple sclerosis	74
The MoXFo initiative – study design: Considerations related to study design and methodology in exercise research for people with multiple sclerosis	63
Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Commentary	61
Therapy challenges for NMOSD in a patient with HIV	55
An interdisciplinary approach is necessary in the treatment of cognitive decline in MS: No	54
Impact of cancer on multiple sclerosis–related healthcare and disease-modifying drug use: A multinational cohort study	51
Characterizing financial toxicity among people living with neuromyelitis optica spectrum disorder	50
Erratum to “Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis” Multiple Sclerosis Journal; 2024: 30(8); 1086–1088.	48
Severe course of tick-borne encephalitis (TBE) in a patient with relapsing multiple sclerosis (MS) treated with ocrelizumab	46
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial	42
Spinal cord imaging for multiple sclerosis: Advances, priorities, and opportunities	42
Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series	40
Cortical ischemic lesions from atrial myxoma as a mimic of disease activity in an RRMS antiCD20-treated patient	39
Cladribine in multiple sclerosis with autoimmune comorbidities: Further clinical insights from patients with rheumatologic disease treated in combination with secukinumab	38
Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity	37
Dietary habits and advanced imaging/laboratory markers in multiple sclerosis: An exploratory cross-sectional study	37
Longitudinal magnetic resonance spectroscopy study of metabolite changes over 2 years in relapsing and primary progressive multiple sclerosis treated with ocrelizumab	36
GM-CSF is a marker of compartmentalised intrathecal inflammation in multiple sclerosis	35
Paramagnetic rim lesions predict greater long-term relapse rates and clinical progression over 10 years	34
Neurophysiological MEG markers of cognitive impairment and performance validity in multiple sclerosis	34
Progression independent of relapse activity in multiple sclerosis: Time to account for cognitive decline	34
Double-negative neuromyelitis optica spectrum disorder	32

Successful alemtuzumab retreatment in multiple sclerosis following previous diffuse alveolar haemorrhage	32
Long-term modifications of the peripheral immune repertoire after switching from sequestering disease-modifying treatments in multiple sclerosis	32
Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study	31
High-risk populations should be screened for MS—Commentary	31
Is there a prodrome to NMOSD? An investigation of neurologic symptoms preceding the first NMOSD attack	31
Comparative effectiveness of rituximab and cladribine in relapsing–remitting multiple sclerosis: A target trial emulation	30
White matter paramagnetic rim and non-rim lesions share a periventricular gradient in multiple sclerosis: A 7-T imaging study	30